TC
ITCI

TwinBeech Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

TwinBeech Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-45,807
Closed -$3.35M – 986
2024
Q3 		$3.35M Buy
+45,807
New +$3.44M 0.06% 328
2023
Q4 		– Sell
-92,899
Closed -$4.84M – 946
2023
Q3 		$4.84M Buy
+92,899
New +$5.41M 0.09% 266
2022
Q4 		– Sell
-107,391
Closed -$5M – 982
2022
Q3 		$5M Buy
+107,391
New +$5.61M 0.13% 191
2022
Q2 		– Sell
-12,317
Closed -$754K – 759
2022
Q1 		$754K Buy
+12,317
New +$640K 0.03% 362
2021
Q3 		– Sell
-19,794
Closed -$808K – 795
2021
Q2 		$808K Buy
+19,794
New +$732K 0.1% 240

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

TwinBeech Capital's ITCI Position: Q4 2024 in Review

TwinBeech Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2024, closing a stake of 45,807 shares — an estimated $3.35M sold.

TwinBeech Capital first reported a position in ITCI in Q2 2021 and held it in 5 quarters. The position peaked at $5M in Q3 2022. 387 funds tracked by Wall St. Rank hold ITCI as of Q4 2024.

  • TwinBeech Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2024 after selling out during the quarter.
  • TwinBeech Capital sold 45,807 Intra-Cellular Therapies Inc. shares in Q4 2024, an estimated $3.35M.
  • TwinBeech Capital first reported a position in Intra-Cellular Therapies Inc. in Q2 2021 and held it in 5 quarters.
  • TwinBeech Capital's Intra-Cellular Therapies Inc. position peaked at $5M in Q3 2022.
  • 387 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2024.

Based on TwinBeech Capital's 13F filing for Q4 2024, filed 14 Feb 2025.